Log in

NYSEAMERICAN:XXII22nd Century Group Stock Price, Forecast & News

$0.74
-0.02 (-2.64 %)
(As of 07/3/2020 12:13 PM ET)
Add
Compare
Today's Range
$0.74
Now: $0.74
$0.77
50-Day Range N/A
52-Week Range
$0.60
Now: $0.74
$2.46
Volume807,671 shs
Average Volume1.61 million shs
Market Capitalization$102.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine content cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. It is also involved in contract manufacturing business for third-party branded tobacco products. The company has a strategic research and development agreement with Keygene N.V. to develop hemp/cannabis plants for medical and therapeutic use, and other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
Read More
22nd Century Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
Current SymbolNYSEAMERICAN:XXII
CUSIPN/A
CIKN/A
Phone+1-716-2701523

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees82
Market Cap$102.36 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter.

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of 22nd Century Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for 22nd Century Group.

When is 22nd Century Group's next earnings date?

22nd Century Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for 22nd Century Group.

How were 22nd Century Group's earnings last quarter?

22nd Century Group Inc (NYSEAMERICAN:XXII) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.03) EPS for the quarter. The biotechnology company had revenue of $7.10 million for the quarter. View 22nd Century Group's earnings history.

What price target have analysts set for XXII?

1 brokerages have issued 12-month price objectives for 22nd Century Group's stock. Their forecasts range from $12.00 to $12.00. On average, they expect 22nd Century Group's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 1,527.8% from the stock's current price. View analysts' price targets for 22nd Century Group.

Has 22nd Century Group been receiving favorable news coverage?

News headlines about XXII stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. 22nd Century Group earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about 22nd Century Group.

Who are some of 22nd Century Group's key competitors?

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Cara Therapeutics (CARA), Canopy Growth (CGC), Novavax (NVAX), Cronos Group (CRON), Aurora Cannabis (ACB), KushCo (KSHB), Terra Tech (TRTC), Micron Technology (MU), Zynerba Pharmaceuticals (ZYNE) and Aurora Cannabis (ACBFF).

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the following people:
  • Mr. Henry Sicignano III, MBA, Pres, CEO & Director (Age 51)
  • Mr. John T. Brodfuehrer, CFO & Treasurer (Age 61)
  • Mr. Thomas L. James J.D., Esq., VP, Gen. Counsel & Sec. (Age 60)
  • James Vail, Director of Communications
  • Mr. James C. Morrison, Technical Advisor & Regulatory Affairs Consultant

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $0.74.

How big of a company is 22nd Century Group?

22nd Century Group has a market capitalization of $102.36 million. 22nd Century Group employs 82 workers across the globe.

What is 22nd Century Group's official website?

The official website for 22nd Century Group is www.xxiicentury.com.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.